A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.

ABSTRACT:

Background

Bone-targeted agents are usually administered to breast cancer patients with bone metastases every 3-4 weeks. Less frequent ('de-escalated') treatment may provide similar benefits with improved safety and reduced cost.

Methods

To systematically review randomised trials comparing de-escalated treatment with bone-targeted agents (i.e. every 12-16 weeks) to standard treatment (i.e. every 3-4 weeks), a formal systematic review of the literature was performed. Two individuals independently screened citations and full text articles. Random effects meta-analyses of clinically important outcomes were planned provided homogeneous studies were identified.

Results

Five relevant studies (n=1287 patients) were identified. Sample size ranged from 38 to 425. Information o

SUBMITTER: Hutton B 

PROVIDER: S-EPMC4723383 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature